Identification of Hub Genes and Enriched Gene Ontology & Pathways in Idiopathic Pulmonary Fibrosis Through Bioinformatics Approaches

Year : 2026 | Volume : 13 | Issue : 01 | Page : 1 13
    By

    Elakkiya M.,

  1. Researcher, Department of Biotechnology, M S Ramaiah Institute of Technology, Bengaluru, Karnataka, India

Abstract

Idiopathic Pulmonary Fibrosis (IPF) is a progressive interstitial lung disease marked by aberrant remodeling of lung tissue and excessive extracellular matrix deposition, ultimately leading to respiratory failure. Despite ongoing research, the molecular mechanisms underlying IPF remain incompletely understood. This research aims to uncover differentially expressed genes (DEGs) and related biological pathways through an integrated analysis of microarray data. Two publicly available datasets, GSE110147 and GSE53845, were obtained from the Gene Expression Omnibus (GEO) database. DEGs were determined using the GEO2R tool with selection criteria of log2 fold change > 1 and adjusted p-value < 0.05. Functional annotation and pathway enrichment analyses were conducted via the STRING database to explore key biological processes associated with IPF. Additionally, protein–protein interaction (PPI) networks were generated using STRING to identify potential hub genes. The analysis revealed consistent dysregulation in genes related to extracellular matrix organization, immune response, and fibrosis-associated pathways. Integration of both datasets enhanced the robustness and reliability of DEG identification. The results provide insight into the molecular framework of IPF and suggest potential biomarkers and therapeutic targets. Further experimental validation is warranted to confirm the role of identified genes and pathways, contributing to improved diagnosis and treatment strategies for IPF.

Keywords: Bioinformatics, differentially expressed genes, hub genes, idiopathic pulmonary fibrosis, protein–protein interaction, STRING

[This article belongs to Research & Reviews: A Journal of Bioinformatics ]

How to cite this article:
Elakkiya M.. Identification of Hub Genes and Enriched Gene Ontology & Pathways in Idiopathic Pulmonary Fibrosis Through Bioinformatics Approaches. Research & Reviews: A Journal of Bioinformatics. 2026; 13(01):1-13.
How to cite this URL:
Elakkiya M.. Identification of Hub Genes and Enriched Gene Ontology & Pathways in Idiopathic Pulmonary Fibrosis Through Bioinformatics Approaches. Research & Reviews: A Journal of Bioinformatics. 2026; 13(01):1-13. Available from: https://journals.stmjournals.com/rrjobi/article=2026/view=239628


References

  1. Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941–52.
  2. Zhang TT, Zhang JY, Li Y. Integrated bioinformatics analysis of key candidate genes and therapeutic drugs for idiopathic pulmonary fibrosis. Asian Toxicol Res. 2020;2(4):151–64.
  3. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92.
  4. Varone F, Sgalla G, Iovene B, Bruni T, Richeldi L. Nintedanib for the treatment of idiopathic pulmonary fibrosis. Expert Opin Pharmacother. 2018;19(2):167–75.
  5. Li N, Qiu L, Zeng C, Fang Z, Chen S, Song X, et al. Bioinformatic analysis of differentially expressed genes and pathways in idiopathic pulmonary fibrosis. Ann Transl Med. 2021;9(18):1459.
  6. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING v10: Protein–protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 2015;43(D1):D447–52.
  7. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: A software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.
  8. Li D, Liu Y, Wang B. Identification of transcriptomic markers for developing idiopathic pulmonary fibrosis: An integrative analysis of gene expression profiles. Int J Clin Exp Pathol. 2020;13(7):1698–706.
  9. Blanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell. 2020;181(5):1036–45.
  10. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: The potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807–15.
  11. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: Therapeutic translation for fibrotic disease. Nat Med. 2012;18(7):1028–40.
  12. Todd NW, Atamas SP, Luzina IG, Galvin JR. Permanent alveolar collapse is the predominant mechanism in idiopathic pulmonary fibrosis. Expert Rev Respir Med. 2015;9(4):411–8.
  13. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med. 2001;345(7):517–25.
  14. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3(1):17074.
  15. Wakwaya Y, Brown KK. Idiopathic pulmonary fibrosis: Epidemiology, diagnosis and outcomes. Am J Med Sci. 2019;357(5):359–69.
  16. Zhang HP, Zou J, Xie P, Gao F, Mu H. Association of HLA and cytokine gene polymorphisms with idiopathic pulmonary fibrosis. 2015.
  17. Alhamad EH, Cal JG, Shakoor Z, Almogren A, AlBoukai AA. Cytokine gene polymorphisms and serum cytokine levels in patients with idiopathic pulmonary fibrosis. BMC Med Genet. 2013;14:66.
  18. Xu Z, Mo L, Feng X, Huang M, Li L. Using bioinformatics approach identifies key genes and pathways in idiopathic pulmonary fibrosis. Medicine (Baltimore). 2020;99(36):e22099.
  19. Mahmud SH, Al-Mustanjid M, Akter F, Rahman MS, Ahmed K, Rahman MH, et al. Bioinformatics and system biology approach to identify the influences of SARS-CoV-2 infections to idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease patients. Brief Bioinform. 2021;22(5):bbab115.
Regular Issue Subscription Original Research
Volume 13
Issue 01
Received 11/11/2025
Accepted 31/01/2026
Published 27/03/2026
Publication Time 136 Days
18

Login


My IP

PlumX Metrics